Skip to main content

Table 2 ACR response rates at week 12

From: ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial

  Placebo (n = 33) ASP5094 (n = 32)
ACR50 responders, n (%)a 6 (18.2) 2 (6.3)
 Difference (90% CI) −11.9 (−25.0, 1.2)
P valueb 0.258
ACR20 responders, n (%)c 16 (48.5) 12 (37.5)
 Difference (90% CI) −11.0 (− 31.1, 9.1)
P valueb 0.455
ACR70 responders, n (%)c 2 (6.1) 1 (3.1)
 Difference (90% CI) −2.9 (−11.4, 5.6)
P valueb 1.000
  1. aPrimary efficacy endpoint, assessed via nonresponder imputation
  2. bP values based on Fisher’s exact test
  3. cSecondary efficacy endpoint, assessed via last observation carried forward technique
  4. ACR American College of Rheumatology, CI confidence interval